Front Oncol: Efficacy and safety of apatinib combined with carrelizumab in previously treated patients with advanced cholangiocarcinoma

Biliary tract cancer (BTC) is a group of heterogeneous tumors derived from biliary epithelial cells, usually divided into intrahepatic and extrahepatic cholangiocarcinoma (ICC, ECC) and gallbladder cancer (GBC)
.
Although BTC is traditionally considered a rare malignant tumor, it is the second most common primary liver tumor, accounting for approximately 10%-15% of all hepatobiliary malignancies

.

Biliary tract cancer (BTC) is a group of heterogeneous tumors derived from biliary epithelial cells, usually divided into intrahepatic and extrahepatic cholangiocarcinoma (ICC, ECC) and gallbladder cancer (GBC)

The study included 22 patients, with a median age of 58 years (39-72 years), and 11 patients (52%) were men

.

The study included 22 patients, with a median age of 58 years (39-72 years), and 11 patients (52%) were men

Efficacy evaluation

Efficacy evaluation

According to the RECIST 1.

1 standard, no CR was observed, 4 cases (19%) obtained PR, ORR was 19%, and 11 cases were SD, and the disease control rate (DCR) was 71.

According to the RECIST 1.

Prognosis

Prognosis

All patients experienced at least one adverse event, and 14 of 22 patients (63.

6%) had Grade 3 or 4 AEs

All patients experienced at least one adverse event, and 14 of 22 patients (63.

Treatment-related adverse events

 Treatment-related adverse events

Among 21 available tumor specimens, 4 (19%) tumor cells or immune cells stained positively for PD-L1

.

Among 21 available tumor specimens, 4 (19%) tumor cells or immune cells stained positively for PD-L1

PD-L1 status affects prognosis

PD-L1 status affects prognosis

In summary, this is the first study to evaluate the effectiveness and safety of carrelizumab combined with apatinib in the treatment of patients with biliary tract cancer

.
The results show that the treatment effect of this program is good, and the toxicity is relatively controllable
.

In summary, this is the first study to evaluate the effectiveness and safety of carrelizumab combined with apatinib in the treatment of patients with biliary tract cancer
.
The results show that the treatment effect of this program is good, and the toxicity is relatively controllable
.
This is the first study to evaluate the effectiveness and safety of carrelizumab combined with apatinib in the treatment of patients with biliary tract cancer
.
The results show that the treatment effect of this program is good, and the toxicity is relatively controllable
.
This is the first study to evaluate the effectiveness and safety of carrelizumab combined with apatinib in the treatment of patients with biliary tract cancer
.
The results show that the treatment effect of this program is good, and the toxicity is relatively controllable
.

Original source:

Original source:

Wang D, Yang X, Long J, Lin J, Mao J, Xie F, Wang Y, Wang Y, Xun Z, Bai Y, Yang X, Guan M, Pan J, Seery S, Sang X and Zhao H (2021) The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
Front.
Oncol.
11:646979.
doi: 10.
3389/fonc.
2021.
646979

Wang D, Yang X, Long J, Lin J, Mao J, Xie F, Wang Y, Wang Y, Xun Z, Bai Y, Yang X, Guan M, Pan J, Seery S, Sang X and Zhao H (2021) the Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer:.
.
A Prospective Clinical Study Front Oncol 11:.
646979 doi:.
10.
3389 / fonc.
2021.
646979 in this message